An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels

An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. Eppie M. Yiu, Geneieve Tai, Roger E. Peverill, Katherine J. Lee, Kevin D. Croft, Trevor A. Mori, Barbara Scheiber-Mojdehkar, Brigitte Sturm, Monika Praschberger, Adam P. Vogel, Gary Rance, Sarah E. M. Stephenson, Joseph P. Sarsero, Creina Stockley, Chung-Yung J. Lee, Andrew Churchyard, Marguerite V. Evans-Galea, Monique M. Ryan, Paul J. Lockhart, Louise A. Corben, Martin B. Delatycki; Journal of Neurology, April 2015 DOI 10.1007/s00415-015-7719-2